• 文章类型: Journal Article
    坦桑尼亚的桑给巴尔群岛已成为恶性疟原虫的低传播区。尽管多年来一直被认为是淘汰前的领域,实现淘汰一直很困难,可能是由于来自坦桑尼亚大陆的输入性感染和持续的本地传播。
    为了阐明这些传输源,我们利用分子倒置探针对2016年至2018年在桑给巴尔和沿海大陆Bagamoyo地区收集的282株恶性疟原虫进行了高度多重基因分型,以表征其遗传相关性.
    总的来说,沿海大陆和桑给巴尔群岛的寄生虫种群仍然高度相关。然而,由于在很短的距离内寄生虫相关性的快速衰减,来自桑给巴尔的寄生虫分离物表现出种群微观结构。这个,以及shehias内部高度相关的对,表明正在进行的低级本地传输。我们还确定了整个shehias高度相关的寄生虫,这些寄生虫反映了Unguja主岛上的人类活动,并确定了一系列高度相关的寄生虫,暗示爆发,在彭巴岛的米切韦尼区。无症状感染的寄生虫表现出比有症状感染的寄生虫更高的感染复杂性。但有相似的核心基因组。
    我们的数据支持进口作为遗传多样性的主要来源和对桑给巴尔寄生虫种群的贡献,但它们也显示了局部爆发集群,在这些集群中,有针对性的干预措施对于阻止局部传播至关重要。这些结果突出表明,需要对进口疟疾采取预防措施,并在由于易感宿主和有能力的媒介而仍然接受疟疾复发的地区加强控制措施。
    这项研究由美国国立卫生研究院资助,授予R01AI121558、R01AI137395、R01AI155730、F30AI143172和K24AI134990。瑞典研究委员会也提供了资金,Erling-Persson家庭基金会,和杨基金。RV承认MRC全球传染病分析中心的资助(参考MR/R015600/1),由英国医学研究理事会(MRC)和英国外国共同资助,联邦和发展办公室(FCDO),根据MRC/FCDO协约协议,也是欧盟支持的EDCTP2计划的一部分。RV还承认社区Jameel的资助。
    UNASSIGNED: The Zanzibar archipelago of Tanzania has become a low-transmission area for Plasmodium falciparum. Despite being considered an area of pre-elimination for years, achieving elimination has been difficult, likely due to a combination of imported infections from mainland Tanzania and continued local transmission.
    UNASSIGNED: To shed light on these sources of transmission, we applied highly multiplexed genotyping utilizing molecular inversion probes to characterize the genetic relatedness of 282 P. falciparum isolates collected across Zanzibar and in Bagamoyo district on the coastal mainland from 2016 to 2018.
    UNASSIGNED: Overall, parasite populations on the coastal mainland and Zanzibar archipelago remain highly related. However, parasite isolates from Zanzibar exhibit population microstructure due to the rapid decay of parasite relatedness over very short distances. This, along with highly related pairs within shehias, suggests ongoing low-level local transmission. We also identified highly related parasites across shehias that reflect human mobility on the main island of Unguja and identified a cluster of highly related parasites, suggestive of an outbreak, in the Micheweni district on Pemba island. Parasites in asymptomatic infections demonstrated higher complexity of infection than those in symptomatic infections, but have similar core genomes.
    UNASSIGNED: Our data support importation as a main source of genetic diversity and contribution to the parasite population in Zanzibar, but they also show local outbreak clusters where targeted interventions are essential to block local transmission. These results highlight the need for preventive measures against imported malaria and enhanced control measures in areas that remain receptive to malaria reemergence due to susceptible hosts and competent vectors.
    UNASSIGNED: This research was funded by the National Institutes of Health, grants R01AI121558, R01AI137395, R01AI155730, F30AI143172, and K24AI134990. Funding was also contributed from the Swedish Research Council, Erling-Persson Family Foundation, and the Yang Fund. RV acknowledges funding from the MRC Centre for Global Infectious Disease Analysis (reference MR/R015600/1), jointly funded by the UK Medical Research Council (MRC) and the UK Foreign, Commonwealth & Development Office (FCDO), under the MRC/FCDO Concordat agreement and is also part of the EDCTP2 program supported by the European Union. RV also acknowledges funding by Community Jameel.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    毒理学研究者联盟(ToxIC)是作为接受医学毒理学咨询的病例的前瞻性多中心注册表而启动的。现在,超过10万例,核心注册中心继续解决许多医学毒理学研究问题,并作为多个分注册中心的基础,包括北美蛇咬伤登记处和阿片类药物使用障碍子登记处。ToxIC还开发了一系列非注册项目,利用医疗毒理学医师现场主要调查人员通过急诊科招募患者,不管他们是否接受了医学毒理学咨询。这些研究包括FDA-ACMTCOVID-19有毒物质药物警戒项目,该研究确定了与COVID-19治疗相关的药物不良反应,Fentalog研究是对疑似阿片类药物过量病例的毒性监测研究,药物过量毒性监测报告计划,该计划登记疑似兴奋剂或阿片类药物过量病例,以及刚刚启动的纳洛酮药物过量逆转项目的真实世界检查。鉴于ToxIC在多中心研究方面的经验及其发达的基础设施,它处于有利地位,可以为医学毒理学界提供灵活的应对措施,以应对不断发展的毒理学威胁,药物和化学毒物监测,和其他重要的医学毒理学优先事项。
    The Toxicology Investigators Consortium (ToxIC) was launched as a prospective multi-center registry of cases who receive medical toxicology consultations. Now, with over 100,000 cases, the Core Registry continues to address many medical toxicology research questions and has served as the foundation for multiple sub-registries, including the North American Snakebite Registry and the Medications for Opioid Use Disorder sub-registry. ToxIC also has evolved a portfolio of non-registry-based projects utilizing medical toxicology physician site principal investigators who enroll patients through emergency departments, irrespective of whether they received a medical toxicology consultation. These studies include the FDA-ACMT COVID-19 ToxIC Pharmacovigilance Project, which identifies adverse drug reactions related to the treatment of COVID-19, the Fentalog Study a toxico-surveillance study of suspected opioid overdose cases, the Drug Overdose Toxico-Surveillance Reporting Program which enrolls either suspected stimulant or opioid overdose cases, and the just being launched Real-World Examination of Naloxone for Drug Overdose Reversal project. Given ToxIC\'s experience in multi-center studies and its well-developed infrastructure, it is well-positioned to provide a nimble response on the part of the medical toxicology community to addressing evolving toxicological threats, drug and chemical toxicosurveillance, and other important medical toxicology priorities.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    分化差与皮肤鳞状细胞癌(CSCC)的不良预后密切相关。此外,国家综合癌症网络(NCCN)指南将低分化肿瘤指定为“非常高风险”。尽管有明确的预后意义,目前普遍使用的CSCC分化没有标准化的分级系统。皮肤病理学家和Mohs外科医生的CSCC分化分级不一致,可靠性研究表明,这两组的评分者间和评分者内可靠性都不理想。缺乏标准化和可靠的分级系统阻碍了在CSCC分期中区分的使用,尽管它与疾病结局明显相关。我们对总结历史CSCC差异化分级系统的文献进行了全面回顾,以及非皮肤性头颈部SCC的分级系统作为参考点。相关文章是通过搜索Embase和PubMed确定的,以及通过查看其他文章和组织学教科书摘录的参考列表。识别和总结的CSCC分级系统包括历史Broders系统,世界卫生组织系统,美国病理学家学院系统,和2023年Delphi皮肤病理学家共识小组描述的系统。
    Poor differentiation is strongly associated with poor outcomes in cutaneous squamous cell carcinoma (CSCC). In addition, the National Comprehensive Cancer Network (NCCN) guidelines designate poorly differentiated tumors as \"very high risk\". Despite its clear prognostic implications, there is no standardized grading system for CSCC differentiation in common use today. CSCC differentiation is graded inconsistently by both dermatopathologists and Mohs surgeons, and reliability studies have demonstrated suboptimal inter- and intra-rater reliability in both of these groups. The absence of a standardized and reliable grading system has impeded the use of differentiation in CSCC staging, despite its apparent correlation with disease outcomes. We performed a comprehensive review of the literature summarizing historical CSCC differentiation grading systems, as well as grading systems in non-cutaneous head and neck SCC as a point of reference. Relevant articles were identified by searching Embase and PubMed, as well as by reviewing reference lists for additional articles and histology textbook excerpts. CSCC grading systems that were identified and summarized include the historical Broders system, the World Health Organization system, the College of American Pathologists\' system, and a system described by a 2023 Delphi consensus panel of dermatopathologists.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    目的:围手术期化疗联合手术切除是局部进展期胃癌治疗的金标准。Mandard肿瘤消退评分(TRG)被广泛用于评估对新辅助治疗的病理反应。这项研究的目的是评估TRG在总体生存率(OS)和无病生存率(DFS)方面的预后价值。
    方法:回顾性分析2007年1月至2019年12月所有新辅助化疗后行肿瘤胃切除术的胃腺癌患者。根据其TRG状态,将其分为两组:良好反应者(TRG1-2)和不良反应者(TRG3-5)。随后进行多变量分析。
    结果:纳入74例患者,其中15(20.3%)为TRG1-2。TRG1-2的新辅助疗法与TRG3-5相似:MAGIC(53%vs.39%),FLOT(40%与36%),FOLFOX(7%vs.15%,p=0.462)。根据TRG1-2的Lauren分类的组织学类型与TRG3-5分别为:13%与29%的肠道,53%vs.44%扩散和34%与27%不确定(p=0.326)。TRG1-2组的ypT明显较低(46%vs.10%,p=0.001)和ypN阶段(66%与37%,p=0.008),同时复发率降低(20%vs.42%,p=0.111)。该组的3年DFS明显更好(81%vs.47%,p=0.041),而三年OS的差异(92%与55%,p=0.054)没有达到统计学意义。
    结论:与TRG3-5患者相比,TRG1-2患者的ypT和ypN分期较低,DFS较好,对操作系统没有重大影响。
    OBJECTIVE: Perioperative chemotherapy combined with surgical resection represent the gold standard in the treatment of locally advanced gastric cancer. The Mandard tumor regression score (TRG) is widely used to evaluate pathological response to neoadjuvant treatment. The aim of this study was to assess the prognostic value of TRG in terms of overall survival (OS) and disease-free (DFS).
    METHODS: Retrospective analysis of all consecutive patients who underwent oncological gastrectomy after neoadjuvant chemotherapy from January 2007 to December 2019 for gastric adenocarcinoma was performed. Based on their TRG status they were categorized into two groups: good responders (TRG 1-2) and poor responders (TRG 3-5). Subsequent multivariable analyses were conducted.
    RESULTS: Seventy-four patients were included, whereby 15 (20.3%) were TRG 1-2. Neoadjuvant regimens for TRG 1-2 vs. TRG 3-5 were similar: MAGIC (53% vs. 39%), FLOT (40% vs. 36%), FOLFOX (7% vs. 15%, p = 0.462). Histologic types according to Lauren classification for TRG 1-2 vs. TRG 3-5 were: 13% vs. 29% intestinal, 53% vs. 44% diffuse and 34% vs. 27% indeterminate (p = 0.326). TRG 1-2 group exhibited significantly less advanced ypT (46% vs. 10%, p = 0.001) and ypN stages (66% vs. 37%, p = 0.008), alongside a diminished recurrence rate (20% vs. 42%, p = 0.111). The 3-year DFS was significantly better in this group (81% vs. 47%, p = 0.041) whereas the disparity in three-year OS (92% vs. 55%, p = 0.054) did not attain statistical significance.
    CONCLUSIONS: TRG 1-2 was associated with less advanced ypT and ypN stage and better DFS compared to TRG 3-5 patients, without a significant impact on OS.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    目的:我们的目的是比较在开放腕管松解术中获得的腱鞘膜(TS)和腕横韧带(TCL)活检中淀粉样蛋白沉积发生率的差异。我们假设,当从同一患者获得两个样本时,TCL和TS之间淀粉样蛋白的发生率相似。
    方法:所有主要,我们回顾了2022年1月至2023年9月期间接受淀粉样蛋白活检的选择性开放腕管松解术病例.由病理学家独立评估腱鞘和TCL标本以评估淀粉样蛋白。收集了人口统计数据,并比较了两种样品之间淀粉样蛋白沉积的发生率。协议统计,灵敏度,并计算了TCL的特异性,使用TS作为参考标准。
    结果:总共196例符合1级(n=180)或2级(n=16)活检标准。48例因活检遗漏或实验室处理错误而被排除,留下148个案例可供分析。淀粉样蛋白沉积存在于148个(21%)TS样本中的31个和148个(22%)TCL样本中的33个中。总的来说,148例中,有138例(93%)的TS活检结果与TCL活检结果一致。在TCL和TS活检结果不同的10例中,6例患者有(+)TCL和(-)TS,4例患者在TS有淀粉样蛋白沉积,在TCL无沉积证据。TCL标本的敏感性和特异性分别为87%和95%,分别。阳性和阴性预测值分别为82%和97%,分别。
    结论:对于接受活检的开放性腕管松解术的病例,在21%的TS标本和22%的TCL标本中发现淀粉样蛋白沉积。从同一患者获得的TS和TCL活检结果在93%的病例中一致。淀粉样蛋白的单源活检是一种合理的诊断方法。应进行未来的成本分析,以确定增加两个活检源以提高诊断准确性是否合理。
    方法:预后II.
    OBJECTIVE: Our purpose was to compare differences in the incidence of amyloid deposition in tenosynovium (TS) versus transverse carpal ligament (TCL) biopsies obtained during open carpal tunnel release. We hypothesized that the incidence of amyloid would be similar between TCL and TS when obtaining both specimens from the same patient.
    METHODS: All primary, elective open carpal tunnel release cases that underwent biopsy for amyloid between January 2022 and September 2023 were reviewed. Tenosynovial and TCL specimens were independently evaluated by a pathologist to assess for amyloid. Demographic data were collected, and incidence of amyloid deposition was compared between the two samples. Agreement statistics, sensitivity, and specificity were calculated for TCL, using TS as the reference standard.
    RESULTS: A total of 196 cases met either Tier 1 (n=180) or Tier 2 (n=16) biopsy criteria. Forty-eight cases were excluded for missed biopsies or laboratory processing errors, leaving 148 cases available for analysis. Amyloid deposition was present in 31 out of 148 (21%) TS specimens and 33 out of 148 (22%) TCL specimens. Overall, the results of the TS biopsy agreed with TCL biopsy in 138 out of 148 cases (93%). In the 10 cases for which the results of the TCL and TS biopsy differed, six cases had (+) TCL and (-) TS, and four cases had amyloid deposition in TS without evidence of deposition in the TCL. Sensitivity and specificity values for the TCL specimen were 87% and 95%, respectively. Positive and negative predictive values were 82% and 97%, respectively.
    CONCLUSIONS: For cases of open carpal tunnel release undergoing biopsy, amyloid deposition was noted in 21% of TS specimens and 22% of TCL specimens. Results of TS and TCL biopsies obtained from the same patient agreed in 93% of cases. Single-source biopsy for amyloid represents a reasonable diagnostic approach. Future cost analyses should be performed to determine whether the addition of two biopsy sources to improve diagnostic accuracy is justified.
    METHODS: Prognostic II.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    我们最近引入了MAPLE(MAximum偏似然估计),一种专门为基因组流行病学设计的新的大流行尺度系统发育推断方法。为了满足提高MAPLE性能和可扩展性的需要,这里我们介绍两个关键组件:(1)CMAPLE软件,MAPLE的高度优化的C++重新实现,具有许多新功能和改进;和(2)CMAPLE库,一套应用程序编程接口,以促进将CMAPLE算法集成到现有的系统发育推理包中。值得注意的是,我们已经成功地将CMAPLE集成到广泛使用的IQ-TREE2软件中,使其在科学界迅速采用。这些进步是为未来大流行做好准备的重要一步,为研究人员提供大规模病原体基因组分析的强大工具。
    We have recently introduced MAPLE (MAximum Parsimonious Likelihood Estimation), a new pandemic-scale phylogenetic inference method exclusively designed for genomic epidemiology. In response to the need for enhancing MAPLE\'s performance and scalability, here we present two key components: (1) CMAPLE software, a highly optimized C++ reimplementation of MAPLE with many new features and advancements; and (2) CMAPLE library, a suite of Application Programming Interfaces to facilitate the integration of the CMAPLE algorithm into existing phylogenetic inference packages. Notably, we have successfully integrated CMAPLE into the widely used IQ-TREE 2 software, enabling its rapid adoption in the scientific community. These advancements serve as a vital step towards better preparedness for future pandemics, offering researchers powerful tools for large-scale pathogen genomic analysis.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    背景:推荐选择性内部放射治疗(SIRT)作为<8cm的单独无法切除的HCC的降期(DS)策略。这项研究的目的是报告所有无法切除的HCC在三级中心获得的经验的结果。
    方法:我们进行了回顾性研究,观察性研究使用从2013年10月至2020年6月期间接受SIRT的连续患者收集的数据。如果可以在SIRT后6个月提出治愈性治疗,则认为已达到DS。
    结果:纳入了一百二十七例患者(男性=90%,64±11y),其中112(n=88%)患有肝硬化。在64例患者(50%)中,HCC被分类为BCLCC期,中值直径为61毫米,51例患者(40%)的浸润模式,门静脉侵犯62例(49%)。50名患者(39%)在SIRT后6个月达到DS,其中29例(23%)在4.3个月的中位时间内接受了治愈性治疗:17例(13%)进行了移植,11人(85%)进行了肝切除,1例患者进行了射频消融。有或没有DS的患者的中位总生存期分别为51和10个月,分别(p<0.001)。在获得DS的患者中,接受手术的患者的无进展生存期较高:47个月对11个月(p<0.001).四个变量与DS独立相关:年龄(OR:0.96,95%CI:[0.92,0.99];p=0.032),基线α-甲胎蛋白(OR:1.00,95%CI:[1.00,1.00];p=0.034),HCC分布(OR:0.3,95%CI:[0.11,0.75];p=0.012),和ALBI等级(OR:0.34。95%CI:[0.14,0.80];p=0.014)。
    结论:这些结果表明,SIRT在不可切除的HCC患者中可能是一种有效的治疗方法:约有39%的患者获得了DS,其中一半以上接受了治愈性治疗。
    BACKGROUND: Selective internal radiation therapy (SIRT) is recommended as a downstaging (DS) strategy for solitary unresectable HCC <8 cm. The aim of this study was to report the results of acquired experience in a tertiary center for all unresectable HCCs.
    METHODS: We conducted a retrospective, observational study using data collected from consecutive patients undergoing SIRT between October 2013 and June 2020. DS was considered achieved when a curative treatment could be proposed 6 months after SIRT.
    RESULTS: One hundred twenty-seven patients were included (male = 90%, 64 ± 11 y), of whom 112 (n = 88%) had cirrhosis. HCC was classified as BCLC stage C in 64 patients (50%), with a median diameter of 61 mm, an infiltrative pattern in 51 patients (40%), and portal vein invasion in 62 (49%) patients. Fifty patients (39%) achieved DS 6 months following SIRT, with 29 of them (23%) undergoing curative treatment in a median time of 4.3 months: 17 (13%) were transplanted, 11 (85%) had liver resection, and 1 patient had a radiofrequency ablation. The median overall survival of patients with or without DS was 51 versus 10 months, respectively (p < 0.001). In patients who achieved DS, progression-free survival was higher in patients who underwent surgery: 47 versus 11 months (p < 0.001). Four variables were independently associated with DS: age (OR: 0.96, 95% CI: [0.92, 0.99]; p = 0.032), baseline α-fetoprotein (OR: 1.00, 95% CI: [1.00, 1.00]; p = 0.034), HCC distribution (OR: 0.3, 95% CI: [0.11, 0.75]; p = 0.012), and ALBI grade (OR: 0.34. 95% CI: [0.14, 0.80]; p = 0.014).
    CONCLUSIONS: These results suggest that SIRT in patients with unresectable HCC could be an effective treatment: DS was achieved for around 39% of the patients and more than half of these then underwent curative treatment.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    最近,儿科患者临床上未怀疑的静脉血栓栓塞(VTE)定义的不一致导致建议标准化该术语。临床上未怀疑的VTE(cuVTE)定义为在没有VTE症状或临床病史的患者中对与VTE无关的适应症进行诊断成像时存在VTE。儿科癌症患者中cuVTE的患病率尚不清楚。因此,我们研究的主要目的是确定cuVTE在儿科癌症患者中的患病率.所有患者0-18岁,在哈利法克斯的IWK治疗,新斯科舍省,从2005年8月至2019年12月,已知癌症诊断和至少一项影像学研究符合资格(n=743).对这些患者的所有放射学报告进行了审查(n=18,120)。对于放射学报告,VTE事件被先验标记为cuVTE事件,包括描述性文本,表明血栓形成(包括血栓)的诊断。中心静脉导管相关,血栓形成的动脉瘤,肿瘤血栓形成,非闭塞性血栓,管腔内充盈缺损,或小碎片凝块,用于没有临床病史和/或VTE迹象的患者。审查中总共包括18,120份放射学报告。cuVTE的患病率为5.5%(41/743)。超声心动图和计算机断层扫描具有最高的cuVTE检出率,用于诊断cuVTE的最常见术语是血栓和非闭塞性血栓。cuVTE的诊断与年龄无关,性别,和癌症的类型。未来的工作应集中在简化放射学报告以表征血栓。这些cuVTE发现的临床意义及其在管理中的应用,血栓形成后综合征,与有症状的VTE和无VTE的患者相比,生存率应进一步研究。
    Inconsistencies in the definition of clinically unsuspected venous thromboembolism (VTE) in pediatric patients recently led to the recommendation of standardizing this terminology. Clinically unsuspected VTE (cuVTE) is defined as the presence of VTE on diagnostic imaging performed for indications unrelated to VTE in a patient without symptoms or clinical history of VTE. The prevalence of cuVTE in pediatric cancer patients is unclear. Therefore, the main objective of our study was to determine the prevalence of cuVTE in pediatric cancer patients. All patients 0-18 years old, treated at the IWK in Halifax, Nova Scotia, from August 2005 through December 2019 with a known cancer diagnosis and at least one imaging study were eligible (n = 743). All radiology reports available for these patients were reviewed (n = 18,120). The VTE event was labeled a priori as cuVTE event for radiology reports that included descriptive texts indicating a diagnosis of thrombosis including thrombus, central venous catheter-related, thrombosed aneurysm, tumor thrombosis, non-occlusive thrombus, intraluminal filling defect, or small fragment clot for patients without documentation of clinical history and or signs of VTE. A total of 18,120 radiology reports were included in the review. The prevalence of cuVTE was 5.5% (41/743). Echocardiography and computed tomography had the highest rate of cuVTE detection, and the most common terminologies used to diagnose cuVTE were thrombus and non-occlusive thrombus. The diagnosis of cuVTE was not associated with age, sex, and type of cancer. Future efforts should focus on streamlining radiology reports to characterize thrombi. The clinical significance of these cuVTE findings and their application to management, post-thrombotic syndrome, and survival compared to cases with symptomatic VTE and patients without VTE should be further studied.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    背景:评估PSMAPET/CT在男性MPMRIPI-RADS评分5阴性活检组织学中的准确性。
    方法:从2011年1月至2023年1月,180名PI-RADS评分为5分的男性接受了系统的MPMRI/TRUS活检;25/180(13.9%)患者没有癌症,活检后六个月接受直肠指检,PSA和PSA密度检查,MPMRI和68GaPSMAPET/CT评估(报告了标准化摄取值“SUVmax”)。
    结果:在24/25(96%)患者中,PSA和PSA密度显着降低,此外,PI-RADS评分降低,结果<3;此外,中位SUVmax为7.5.只有1/25(4%)的男性PSA值增加(从10.5到31ng/ml),确认的PI-RADS评分为5,SUVmax为32,重复的前列腺活检显示Gleason评分为9/ISUPGrade5组PCa。
    结论:对PI-RADS评分为5且组织学阴性的男性进行严格随访可降低csPCa缺失的风险,尤其是如果PSMAPET/CT评估与mpMRI降级一致(PI-RADS评分<3)。
    BACKGROUND: To evaluate the accuracy of PSMA PET/CT in men with mpMRI PI-RADS score 5 negative biopsy histology.
    METHODS: From January 2011 to January 2023, 180 men with PI-RADS score 5 underwent systematic plus mpMRI/TRUS biopsy; 25/180 (13.9%) patients had absence of cancer and six months from biopsy were submitted to: digital rectal examination, PSA and PSA density exams, mpMRI and 68GaPSMA PET/CT evaluation (standardized uptake value \"SUVmax\" was reported).
    RESULTS: In 24/25 (96%) patients PSA and PSA density significantly decreased, moreover, the PI-RADS score was downgraded resulting < 3; in addition, median SUVmax was 7.5. Only 1/25 (4%) man had an increased PSA value (from 10.5 to 31 ng/ml) with a confirmed PI-RADS score 5, SUVmax of 32 and repeated prostate biopsy demonstrating a Gleason score 9/ISUP Grade Group 5 PCa.
    CONCLUSIONS: The strict follow up of men with PI-RADS score 5 and negative histology reduce the risk of missing csPCa especially if PSMA PET/CT evaluation is in agreement with downgrading of mpMRI (PI-RADS score < 3).
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    黑素瘤检测的标准度量是活检所需的数量(NNB)。该指标已用于评估执业皮肤科医生,皮肤科高级实践专业人员,和初级保健提供者。这个指标,然而,很少应用于住院医师诊所。我们旨在确定科罗拉多大学住院医师诊所的NNB。此外,我们试图确定2019年冠状病毒病(COVID-19)大流行对NNB的影响。这项研究是对2016年至2022年在丹佛健康医学中心和落基山地区退伍军人事务皮肤科诊所进行的活检的回顾性分析。活检时的鉴别诊断搜索关键词,包括黑色素瘤,原位黑色素瘤,还有恶性扁豆.排除包括再切除的皮肤活检。随后通过将活检的疑似黑素瘤病变的数量除以组织学证实的黑素瘤的数量来产生NNB。数据进一步按COVID-19之前的数据(2016-2020年2月)分开,COVID-19关闭期(2020年3月至2020年7月),和后COVID-19(2020年3月至今)。人口统计数据,包括年龄,性别,种族,和Fitzpatrick类型,被收集。从2016年到2022年,在两个临床地点的鉴别诊断中均有2230例疑似黑色素瘤的活检。其中,362例经组织学证实为黑色素瘤。NNB总数为6.16。前COVID-19NNB为5.86,后COVID-19NNB为6.91。住院医师诊所的NNB与执业皮肤科医生的公开值相似。此外,在这些诊所里,COVID-19大流行的影响得到了一位亲戚的赞赏,虽然统计上微不足道,NNB的增加。
    A standard metric for melanoma detection is the number needed to biopsy (NNB). This metric has been used to evaluate practicing dermatologists, dermatology advanced practice professionals, and primary care providers. This metric, however, has rarely been applied to residency clinics. We aimed to determine the NNB at the University of Colorado residency clinics. Moreover, we sought to determine the impact of the coronavirus disease 2019 (COVID-19) pandemic on NNB. This study is a retrospective analysis of biopsies performed from 2016 to 2022 at the Denver Health Medical Center and the Rocky Mountain Regional Veteran Affairs dermatology clinics. Differential diagnosis at the time of biopsy was searched for keywords including melanoma, melanoma in situ, and lentigo maligna. Skin biopsies that included re-excisions were excluded. The NNB was subsequently generated by dividing the number of biopsied lesions with suspected melanoma by the number of histologically confirmed melanomas. The data was further separated by pre-COVID-19 (2016-February 2020), COVID-19 shutdown period (March 2020-July 2020), and post-COVID-19 (March 2020-present). Demographic data, including age, sex, race, and Fitzpatrick type, were collected. There were 2230 biopsies with suspected melanoma in the differential diagnosis at both clinic sites from 2016 to 2022. Of these, 362 were histologically confirmed melanoma. Total NNB was 6.16. The pre-COVID-19 NNB was 5.86, and the post-COVID-19 NNB was 6.91. Residency clinics have NNB similar to published values of practicing dermatologists. Furthermore, within these clinics, the impact of the COVID-19 pandemic was appreciated by a relative, although statistically insignificant, increase in NNB.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

公众号